METHODS

This is a descriptive study of pregnant patients who received nirmatrelvir–ritonavir therapy from April 16, 2022 (when the therapy was first prescribed in our practice setting), through May 18, 2022. Patients were eligible to receive nirmatrelvir–ritonavir if they were diagnosed with mild-to-moderate COVID-19 (based on positive results on nasopharyngeal polymerase chain reaction testing for severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), had symptom onset in the previous 5 days, were not requiring oxygen therapy, otherwise did not meet criteria for hospital admission, and had no contraindications to nirmatrelvir–ritonavir. Both vaccinated and unvaccinated patients who met these criteria were eligible to receive nirmatrelvir–ritonavir. After treatment, patients were contacted 8–10 days from the onset of symptoms to assess for treatment completion, adverse treatment effects, and symptom resolution.